mavorixafor will raise the amount or influence of triazolam by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe. Check for adverse results of delicate CYP3A4 substrates if coadministered with mavorixafor (a weak CYP3A4 inhibitor).Stay away from concomitant utilization of tucatinib with CYP3A substrates, where minimum con… Read More